AUPH
Income statement / Annual
Last year (2023), Aurinia Pharmaceuticals Inc.'s total revenue was $175.51 M,
an increase of 30.95% from the previous year.
In 2023, Aurinia Pharmaceuticals Inc.'s net income was -$78.02 M.
See Aurinia Pharmaceuticals Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$175.51 M
|
$134.03 M
|
$45.61 M
|
$50.12 M
|
$318,000.00
|
$463,000.00
|
$420,000.00
|
$173,000.00
|
$235,000.00
|
$278,000.00
|
Cost of Revenue |
$14.15 M |
$5.66 M |
$1.09 M |
$50.33 M |
$52.87 M |
$41.38 M |
$1,000.00 |
$4,000.00 |
$12,000.00 |
$37,000.00 |
Gross Profit |
$161.37 M |
$128.37 M |
$44.51 M |
-$209,000.00 |
-$52.55 M |
-$40.92 M |
$419,000.00 |
$169,000.00 |
$223,000.00 |
$241,000.00 |
Gross Profit Ratio |
0.92 |
0.96 |
0.98 |
-0 |
-165.25 |
-88.38 |
1 |
0.98 |
0.95 |
0.87 |
Research and Development
Expenses |
$49.64 M
|
$44.99 M
|
$51.14 M
|
$50.33 M
|
$52.87 M
|
$41.38 M
|
$33.93 M
|
$14.53 M
|
$15.98 M
|
$9.11 M
|
General & Administrative
Expenses |
$195.04 M
|
$196.37 M
|
$171.44 M
|
$95.98 M
|
$22.15 M
|
$13.67 M
|
$12.10 M
|
$6.97 M
|
$6.26 M
|
$6.89 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$195.04 M
|
$196.37 M
|
$171.44 M
|
$95.98 M
|
$22.15 M
|
$13.67 M
|
$12.10 M
|
$6.97 M
|
$6.26 M
|
$6.89 M
|
Other Expenses |
$8.38 M |
-$1.52 M |
$2.67 M |
$1.29 M |
$1.55 M |
$2.07 M |
$195,000.00 |
-$1.63 M |
-$337,000.00 |
-$848,000.00 |
Operating Expenses |
$244.68 M |
$239.84 M |
$225.25 M |
$147.60 M |
$76.57 M |
$56.62 M |
$47.48 M |
$22.98 M |
$23.80 M |
$17.52 M |
Cost And Expenses |
$258.83 M |
$245.50 M |
$226.34 M |
$147.60 M |
$76.57 M |
$56.62 M |
$47.48 M |
$22.99 M |
$23.82 M |
$17.56 M |
Interest Income |
$17.00 M |
$5.12 M |
$529,000.00 |
$1.52 M |
$2.70 M |
$2.23 M |
$1.04 M |
$27,000.00 |
$50,000.00 |
$65,000.00 |
Interest Expense |
$2.78 M |
$5.12 M |
$0.00 |
$0.00 |
$39,000.00 |
$2.23 M |
$702,000.00 |
$27,000.00 |
$50,000.00 |
$30,000.00 |
Depreciation &
Amortization |
$11.65 M
|
$2.71 M
|
$2.76 M
|
$1.37 M
|
$1.17 M
|
$1.57 M
|
$1.46 M
|
$1.48 M
|
$1.56 M
|
$1.52 M
|
EBITDA |
-$71.67 M
|
-$111.47 M
|
-$178.64 M
|
-$96.19 M
|
-$80.99 M
|
-$44.64 M
|
-$21.68 M
|
-$20.83 M
|
-$26.95 M
|
-$15.70 M
|
EBITDA Ratio |
-0.41 |
-0.83 |
-3.92 |
-1.92 |
-254.69 |
-96.41 |
-51.63 |
-120.39 |
-114.66 |
-56.46 |
Operating Income Ratio
|
-0.47
|
-0.83
|
-3.96
|
-2.08
|
-259.56
|
-121.29
|
-112.05
|
-131.87
|
-100.34
|
-62.17
|
Total Other
Income/Expenses Net |
$5.84 M
|
$5.12 M
|
$529,000.00
|
$1.52 M
|
-$41.16 M
|
-$7.89 M
|
-$23.73 M
|
-$508,000.00
|
$4.92 M
|
$600,000.00
|
Income Before Tax |
-$77.47 M |
-$106.35 M |
-$180.21 M |
-$102.77 M |
-$123.70 M |
-$64.05 M |
-$70.79 M |
-$23.30 M |
-$18.61 M |
-$16.65 M |
Income Before Tax Ratio
|
-0.44
|
-0.79
|
-3.95
|
-2.05
|
-389
|
-138.33
|
-168.55
|
-134.65
|
-79.18
|
-59.88
|
Income Tax Expense |
$551,000.00 |
$1.83 M |
$760,000.00 |
-$94,000.00 |
$144,000.00 |
$73,000.00 |
$23.92 M |
$481,000.00 |
-$4.97 M |
$30,000.00 |
Net Income |
-$78.02 M |
-$108.18 M |
-$180.97 M |
-$102.68 M |
-$123.85 M |
-$64.12 M |
-$70.79 M |
-$23.30 M |
-$18.61 M |
-$16.65 M |
Net Income Ratio |
-0.44 |
-0.81 |
-3.97 |
-2.05 |
-389.45 |
-138.49 |
-168.55 |
-134.65 |
-79.18 |
-59.88 |
EPS |
-0.54 |
-0.76 |
-1.4 |
-0.87 |
-1.33 |
-0.76 |
-0.92 |
-0.66 |
-0.58 |
-0.57 |
EPS Diluted |
-0.54 |
-0.76 |
-1.4 |
-0.87 |
-1.33 |
-0.76 |
-0.92 |
-0.66 |
-0.58 |
-0.57 |
Weighted Average Shares
Out |
$143.24 M
|
$141.92 M
|
$129.37 M
|
$118.47 M
|
$93.02 M
|
$84.78 M
|
$76.92 M
|
$35.29 M
|
$32.15 M
|
$28.99 M
|
Weighted Average Shares
Out Diluted |
$143.24 M
|
$141.92 M
|
$129.37 M
|
$118.47 M
|
$93.02 M
|
$84.78 M
|
$76.95 M
|
$35.29 M
|
$32.15 M
|
$29.16 M
|
Link |
|
|
|
|
|
|
|
|
|
|